Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

Singapore's Largest Medical Aesthetics Group Debuts Tech-Based Hair Growth Solutions Designed By Doctors

SINGAPORE - Media OutReach Newswire - 26 August 2024 - V Medical Aesthetics Group, a leader in Singapore's aesthetics industry with 17 outlets and a comprehensive range of head-to-toe solu...

Premium Passports Lose Their Shine in a Post-pandemic World

LONDON, July 7, 2020, /PRNewswire-AsiaNet/-- As parts of the globe cautiously begin to open up, the focus is on what travel freedom and global mobility will look like in a post–Covid-1...

Tips to Create a Local Impact Using Personalized Outreach

Reaching out to people on a more personal level can have a huge impact on the global arena of digital communication.  Whether you're a nonprofit or a small company, reaching out to people...

Round Hill Capital Receives Strategic Minority Investment from...

LONDON, July 3, 2018 /PRNewswire-AsiaNet/ -- Round Hill Capital ("Round Hill"), a leading real estate investment, development and asset management firm, announces that Dyal Capital Partners...

PostEra Closes $24M in New Financing to Advance Drug Discovery

BOSTON, Jan. 11, 2022 /PRNewswire-AsiaNet/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to ac...

TAISE 3rd Asia-Pacific Sustainability Action Awards Embarking on a Sustainable New Journey

TAIPEI, TAIWAN - Media OutReach Newswire - 6 May 2024 - Aligning the United Nations Sustainable Development Goals (SDGs), the third Asia-Pacific Sustainability Action Awards will soon be he...

FARO(R) Launches Latest Vantage Laser Tracker 6DoF Probe

LAKE MARY, Florida, Nov. 25, 2020 /PRNewswire-AsiaNet/ -- --Highest-accuracy portable inspection tool faster and easier to use--FARO(R) Technologies, Inc. (Nasdaq: FARO), a global leader fo...

Toyota Reproduces and Sells Spare Parts for A70 and A80 Supra

TOKYO, Jan 9, 2020 - (JCN Newswire) - Toyota announces that it will reproduce spare parts for the A70-(1) and A80-model(2) Supra as GR Heritage Parts Project, and will sell them both domest...

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference

TOKYO, Dec 2, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that three oral presentations and eight poster presentations, highlighting the latest data on its Alzheimer's disease / dementia pipeline including anti-amyloid beta (Abeta) protofibril antibody BAN2401, orexin receptor antagonist lemborexant and a simple blood diagnostic for Alzheimer's disease (AD), will be given at the 12th Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in San Diego, California in the United States, from December 4 to 7, 2019. BAN2401 is being jointly developed by Eisai and Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation.

For BAN2401, the persistance of brain Abeta levels in patients with early AD at the beginning of the open label extension phase of the Phase II study (Study 201) will be presented in Late-Breaking Oral Communications Session. Study 201 is a first late-stage study which successfully demonstrated the potential disease-modifying effects on both clinical function and Abeta accumulation in the brain. In addition, the study design and current status of ongoing Clarity AD (Study 301) will be presented.

Meanwhile, for the investigational sleep-wake regulation agent lemborexant, the further data analysis results from Phase II clinical study (Study 202) for AD patients with irregular sleep-wake rhythm disorder (ISWRD) will be given.

In addition, regarding the creation of the simplified blood diagnostics for AD, jointly developed with Sysmex, the latest data of the fully automated protein assay system using the Sysmex's automated protein measurement immunoassay platform HISCLTM series will be presented.Eisai is aiming to realize prevention and cure of dementia through a holistic approach to dementia drug discovery research based on a foundation of over 35 years of experience of drug discovery activities in the area of Alzheimer's disease / dementia. Eisai is striving to create innovative medicines as soon as possible in order to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, patients and their families.

About BAN2401

BAN2401 is a humanized monoclonal antibody for Alzheimer's disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic. BAN2401 selectively binds to neutralize and eliminate soluble, toxic Abeta aggregates (protofibril) that are thought to contribute to the neurodegenerative process in AD. As such, BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of AD pursuant to an agreement concluded with BioArctic in December 2007. Currently, a global clinical phase III study (Clarity AD) of BAN2401 in early AD is underway.

About the Joint Development Agreement between Eisai and Biogen for AD

Eisai and Biogen are widely collaborating on the joint development and commercialization of AD treatments. Eisai serves as the lead in the co-development of BAN2401, an anti-Abeta protofibril antibody, while Biogen serves as the lead for co-development of aducanumab, Biogen's investigational anti-Abeta antibody for patients with AD, and the companies plan to pursue marketing authorizations for the two compounds worldwide. If approved, the companies will also co-promote the products in major markets, such as the United States, the European Union and Japan.

About Lemborexant

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Faster on/off receptor kinetics of lemborexant to orexin receptor 2, which also suppresses non-REM sleep, indicate its potential to be facilitate the onset and maintenance of sleep. As a result of clinical studies, the effect of lemborexant are suggested not only for primary insomnia but also for insomnia which the diseases, such as depression, associated with. Eisai has submitted new drug applications seeking approval of lemborexant for use in the treatment of insomnia disorder in the United States (December 2018), Japan (March 2019), and Canada (August 2019), respectively. Additionally, a Phase II clinical study of lemborexant in patients with ISWRD associated with mild to moderate Alzheimer's dementia is underway.

About collaboration between Eisai and Sysmex

Eisai and Sysmex have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia in February, 2016. Leveraging each other's technologies and knowledge, the two companies aim to discover next-generation diagnostics that will enable early diagnosis, selection of treatment options and the regular monitoring of the effects of treatment for dementia.

HISCLTM is a trademark of Sysmex Corporation.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120

Copyright 2019 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastStreamEastjojobetcialis 20 mg fiyat